Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Gross Profit (2020 - 2025)

Vivos Therapeutics' Gross Profit history spans 6 years, with the latest figure at $3.0 million for Q4 2025.

  • Quarterly results put Gross Profit at $3.0 million for Q4 2025, up 42.49% from a year ago — trailing twelve months through Dec 2025 was $10.5 million (up 16.91% YoY), and the annual figure for FY2025 was $10.5 million, up 16.89%.
  • Gross Profit for Q4 2025 was $3.0 million at Vivos Therapeutics, down from $3.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $3.9 million in Q3 2025 to a low of $1.5 million in Q1 2025.
  • The 5-year median for Gross Profit is $2.4 million (2022), against an average of $2.5 million.
  • The sharpest move saw Gross Profit tumbled 30.01% in 2023, then surged 68.68% in 2025.
  • Year by year, Gross Profit stood at $3.1 million in 2021, then fell by 23.27% to $2.4 million in 2022, then fell by 12.37% to $2.1 million in 2023, then grew by 0.38% to $2.1 million in 2024, then soared by 42.49% to $3.0 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $3.0 million, $3.9 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.